Tenon Medical Reports 2026 Annual Meeting Voting Results

What Happened

• Tenon Medical, Inc. (TNON) filed an 8-K reporting the results of its virtual 2026 Annual Meeting held July 23, 2026 (record date June 8, 2026). A quorum was present with 6,471,472 voting shares (52.98%) represented.
• All seven director nominees were elected by plurality voting. Shareholders also approved the appointment of Haskell & Whitee LLP as independent registered public accounting firm, approved a reverse stock split (board to choose final ratio between 1-for-2 and 1-for-35), and approved related Nasdaq compliance votes tied to debt financings and potential future issuances.

Key Details

• Shares outstanding as of the record date: 11,849,674 common shares (11,849,674 votes); 204,159 Series A preferred (255,184 votes); 86,454 Series B preferred (108,074 votes).
• Reverse stock split proposal: Approved. Vote — For 4,583,877; Against 1,723,195; Abstentions 164,400. Board has discretion to set final ratio between 1:2 and 1:35.
• Auditor appointment: Haskell & Whitee LLP ratified. Vote — For 5,795,018; Against 149,616; Abstentions 526,838.
• Financing-related approvals: (1) Issuance of shares underlying convertible notes from the March 11, 2026 debt financing (which may exceed 19.99% of outstanding shares as of that date) — Approved (For 3,742,855; Against 1,005,184; Abstentions 68,667). (2) Approval under Nasdaq Rule 5635(d) for certain future issuances priced below the Minimum Price — Approved (For 3,653,331; Against 1,080,498; Abstentions 82,877).

Why It Matters

• The reverse split approval gives the board power to consolidate shares (1:2 to 1:35), which will reduce share count and increase per‑share price if executed — a common step to meet exchange listing or marketability targets.
• Shareholder approval for the convertible-note issuances and Nasdaq-related waivers clears regulatory hurdles allowing prior and potential equity issuances tied to the company’s March 2026 financing and future financings.
• Ratifying a new auditor and electing the board completes key governance actions for 2026; investors should watch for any announced reverse split ratio and subsequent filings disclosing timing and effects.